{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"13"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"2"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"title":"grade 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"43"},{"groupId":"OG003","value":"43"},{"groupId":"OG004","value":"43"},{"groupId":"OG005","value":"43"},{"groupId":"OG006","value":"43"},{"groupId":"OG007","value":"43"},{"groupId":"OG008","value":"43"},{"groupId":"OG009","value":"43"}],"units":"Participants"}],"description":"Number of participants with acute grade III/IV treatment-related toxicities","groups":[{"description":"Lymphopenia\n\nParticipant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week","id":"OG000","title":"Lymphopenia"},{"description":"Neutropenia\n\nParticipant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week","id":"OG001","title":"Neutropenia"},{"description":"Anemia\n\nParticipant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week","id":"OG002","title":"Anemia"},{"description":"Oral mucositis\n\nParticipant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week","id":"OG003","title":"Oral Mucositis"},{"description":"Radiation dermatitis\n\nParticipant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week","id":"OG004","title":"Radiation Dermatitis"},{"description":"Acneiform skin rash\n\nParticipant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week","id":"OG005","title":"Acneiform Skin Rash"},{"description":"Dysphagia\n\nParticipant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week","id":"OG006","title":"Dysphagia"},{"description":"Anorexia\n\nParticipant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week","id":"OG007","title":"Anorexia"},{"description":"Nausia/vomiting\n\nParticipant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week","id":"OG008","title":"Nausia/Vomiting"},{"description":"Dehydration\n\nParticipant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week","id":"OG009","title":"Dehydration"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants enrolled in study","reportingStatus":"POSTED","timeFrame":"evaluated every 2 weeks, up to 3 years","title":"Number of Participants With Acute Grade III/IV Treatment-related Toxicities","type":"SECONDARY","unitOfMeasure":"Participants"}